טוען...
IMMU-05. CSF METABOLOMICS AS A PREDICTOR OF SURVIVAL IN PATIENTS WITH BRAIN METASTASIS RECEIVING IMMUNOTHERAPY
INTRODUCTION: Checkpoint inhibitors show a positive intracranial response in around 20–50% of patients with metastatic melanoma and non-small cell lung cancer (NSCLC). There is a current paucity of biomarkers to prospectively identify these patients. We hypothesize that CSF would provide useful data...
שמור ב:
| הוצא לאור ב: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Oxford University Press
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7651074/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.436 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|